Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight

Dow Jones

2024-11-05

By Sabela Ojea

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.

"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test," the company said.

Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added.

The company is expected to post third-quarter results after the market close Thursday.

Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

November 04, 2024 11:38 ET (16:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2481536976"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481536976\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481536976?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 00:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481536976","market":"sg","top_or_hot":-1,"title":"Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n</p>\n<p>\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n</p>\n<p>\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n</p>\n<p>\n  The company is expected to post third-quarter results after the market close Thursday. \n</p>\n<p>\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2024 11:38 ET (16:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-05 00:38</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Sabela Ojea \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n</p>\n<p>\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n</p>\n<p>\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n</p>\n<p>\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n</p>\n<p>\n  The company is expected to post third-quarter results after the market close Thursday. \n</p>\n<p>\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2024 11:38 ET (16:38 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03650","symbol_name":"KEEP","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481536976","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481536976","pubTimestamp":1730738280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.\"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said.Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added.The company is expected to post third-quarter results after the market close Thursday.Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three mo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03650":"KEEP","BK4139":"生物科技","MYGN":"万基遗传","BK1215":"特殊消费者服务"},"translate_title":"Myriad Genetics正在与UnitedHealthcare积极谈判，以保持GeneSight的覆盖范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03650":1,"MYGN":1},"content_text":"By Sabela Ojea \n\n\n \n\n\n  Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy. \n\n\n  The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses. \n\n\n  \"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test,\" the company said. \n\n\n  Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added. \n\n\n  The company is expected to post third-quarter results after the market close Thursday. \n\n\n  Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months. \n\n\n \n\n\n  Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 11:38 ET (16:38 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}